Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
View ORCID ProfilePratha Sah, Thomas N. Vilches, Affan Shoukat, Meagan C. Fitzpatrick, Abhishek Pandey, Burton H. Singer, Seyed M. Moghadas, Alison P. Galvani
doi: https://doi.org/10.1101/2021.05.10.21256996
Pratha Sah
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
Thomas N. Vilches
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
2Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada
Affan Shoukat
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
Meagan C. Fitzpatrick
3Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
Abhishek Pandey
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
Burton H. Singer
4Emerging Pathogens Institute, University of Florida, P.O. Box 100009, Gainesville, FL 32610, USA
Seyed M. Moghadas
2Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada
Alison P. Galvani
1Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
Data Availability
All data are available in the main text or the supplementary materials. The simulation codes are available at: https://github.com/thomasvilches/multiple_strains
Posted August 18, 2021.
Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
Pratha Sah, Thomas N. Vilches, Affan Shoukat, Meagan C. Fitzpatrick, Abhishek Pandey, Burton H. Singer, Seyed M. Moghadas, Alison P. Galvani
medRxiv 2021.05.10.21256996; doi: https://doi.org/10.1101/2021.05.10.21256996
Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
Pratha Sah, Thomas N. Vilches, Affan Shoukat, Meagan C. Fitzpatrick, Abhishek Pandey, Burton H. Singer, Seyed M. Moghadas, Alison P. Galvani
medRxiv 2021.05.10.21256996; doi: https://doi.org/10.1101/2021.05.10.21256996
Subject Area
Subject Areas
- Addiction Medicine (380)
- Allergy and Immunology (695)
- Anesthesia (186)
- Cardiovascular Medicine (2809)
- Dermatology (241)
- Emergency Medicine (424)
- Epidemiology (12499)
- Forensic Medicine (10)
- Gastroenterology (796)
- Genetic and Genomic Medicine (4365)
- Geriatric Medicine (398)
- Health Economics (711)
- Health Informatics (2814)
- Health Policy (1042)
- Hematology (372)
- HIV/AIDS (888)
- Medical Education (411)
- Medical Ethics (113)
- Nephrology (460)
- Neurology (4132)
- Nursing (219)
- Nutrition (613)
- Oncology (2178)
- Ophthalmology (616)
- Orthopedics (253)
- Otolaryngology (316)
- Pain Medicine (260)
- Palliative Medicine (80)
- Pathology (482)
- Pediatrics (1166)
- Primary Care Research (480)
- Public and Global Health (6721)
- Radiology and Imaging (1475)
- Respiratory Medicine (893)
- Rheumatology (427)
- Sports Medicine (359)
- Surgery (468)
- Toxicology (57)
- Transplantation (197)
- Urology (173)